Jeeyun Lee
A gastric cancer trialist who pioneered biomarker-driven umbrella trials in Korea and helped bring HER2 and Claudin 18.2 agents to Asian patients.
Jeeyun Lee's group at Samsung Medical Center runs molecularly stratified trials in gastric and other GI cancers (VIKTORY umbrella), and she has been an investigator on zolbetuximab, pembrolizumab, and zanidatamab gastric studies.
| Title | Journal | Year |
|---|---|---|
| Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial | Cancer Discovery | 2019 |
Pages like this
not linked directly; found by shared links- IdeaBiomarker-directed first-line quadruplets in gastric cancer
Shares Zolbetuximab, Zanidatamab, Claudin 18.2, HER2.
- PersonWoong-Yang Park
Shares Samsung Medical Center, Comprehensive genomic profiling.
- PersonWon Ki Kang
Shares Samsung Medical Center, Gastric & gastro-oesophageal junction cancer.
- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
Shares Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonKohei Shitara
Shares Zolbetuximab, Claudin 18.2, HER2, Gastric & gastro-oesophageal junction cancer.
- PersonMin-Hee Ryu
Shares Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- TrialHERIZON-BTC-302
Shares Zanidatamab, HER2.
- PersonYoon-Koo Kang
Shares Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.